Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis
Cycle-to-Cycle Prediction of Absorbed Dose in [ 177 Lu]Lu-PSMA-617 Therapy Using Radiomic and Dosiomic Features from Prior SPECT/CT Imaging (EANM 2026) - Sep 29, 2026 - Abstract #OP-684; Pres time: Oct 20, 2026; 03:00 PM - 04:30 PM; Location: Hall B; "Beyond previously suggested inter-cycle prediction approaches, this work demonstrates the added value of incorporating radiomic features and spatial and voxel-level information beyond global uptake metrics. This framework may be especially valuable when full dosimetry is not feasible, such as missing imaging time points or limited organ coverage, while still supporting adaptive, patient-specific treatment planning." 
https://www.sciencedirect.com/science/article/pii/S3051291326002855?via%3Dihub
 
P. Geramifar 1; E. Yazdani 1, 2; I. Klyuzhin 1, 3; A. Dhalla 1; F. Farhadi 3; B. Saboury 3, 4; C. Uribe 1, 4, 5; A. Rahmim 1, 4, 5; P. Esquinas 1, 4, 5
 
Sep 29, 2026
 
Prev Next